Sunhee Kim

Sunhee Kim

Auto-generated profile, based on publicly available information

Sunhee Kim

Interdisciplinary Program in Medical Informatics, Seoul National University Graduate School, Seoul, Korea

Research Focus & Metrics

Academic Career Length

8Years (2019-Present)

(Calculated once Scilit publication data is synced: current year − year of first publication + 1)

Representative Publications

View All Publications
10 September 2019 in Scientific Reports
Verified
Journal Article
Open access
PDF file
JBJae Hyun Bae
Jae Hyun Bae
EPEun-Gee Park
Eun-Gee Park
SKSunhee Kim
Sunhee Kim
SKSin Gon Kim
Sin Gon Kim
SHSeokyung Hahn
Seokyung Hahn
NKNam Hoon Kim
Nam Hoon Kim
This study was conducted to investigate the effects of sodium-glucose cotransporter 2 (SGLT2) inhibitors on individual renal outcomes in patients with type 2 diabetes. We searched MEDLINE, Embase, and the Cochrane Central Register of Controlled Trials from inception to September 2017 to identify randomized controlled trials comparing SGLT2 inhibitors with placebo or antidiabetic drugs and reporting any renal outcomes in patients with type 2 diabetes. Additionally, we identified 4 articles which were published after the predefined period to include relevant data. A meta-analysis was performed to calculate weighted mean differences (WMDs) and relative risks (RRs) with 95% confidence intervals (CIs) for each renal outcome. We included 48 studies involving 58,165 patients in the analysis. SGLT2 inhibitors significantly lowered urine albumin-to-creatinine ratio (UACR) (WMD, −14.64 mg/g; 95% CI, −25.15 to −4.12;P = 0.006) compared with controls. The UACR-lowering effects of SGLT2 inhibitors were greater with a higher baseline UACR. Overall changes in estimated glomerular filtration rate (eGFR) were comparable between two groups (WMD, 0.19 mL/min/1.73 m2; 95% CI, −0.44 to 0.82;P = 0.552). However, SGLT2 inhibitors significantly slowed eGFR decline in patients with a higher baseline eGFR and a longer duration of treatment. Compared with controls, SGLT2 inhibitors significantly reduced the risk of microalbuminuria (RR, 0.69; 95% CI, 0.49 to 0.97;P = 0.032), macroalbuminuria (RR, 0.49; 95% CI, 0.33 to 0.73;P < 0.001), and worsening nephropathy (RR, 0.73; 95% CI, 0.58 to 0.93;P = 0.012). In addition, the risk of end-stage renal disease was significantly lower in SGLT2 inhibitors than in controls (RR, 0.70; 95% CI, 0.57 to 0.87;P = 0.001). In conclusion, SGLT2 inhibitors had beneficial renal effects by lowering the risk of albuminuria development or progression and reducing the risk of end-stage renal disease compared with placebo or other antidiabetic drugs.

22 August 2019 in Scientific Reports
Verified
Journal Article
Open access
PDF file
SKSunhee Kim
Sunhee Kim
SHSeokyung Hahn
Seokyung Hahn
MJMyoung-Jin Jang
Myoung-Jin Jang
YCYunhee Choi
Yunhee Choi
HHHyunsook Hong
Hyunsook Hong
HKHee-Soo Kim
Hee-Soo Kim
Propofol is one of the most widely used drugs for paediatric procedural sedation owing to its known advantages, but some concerns remain regarding respiratory and/or cardiac complications in patients receiving propofol. Although a considerable number of randomised controlled clinical trials (RCTs) have been conducted to compare it with other sedative agents or opioids for children undergoing various procedures, propofol is still being used off-label for this indication in many countries. We performed a systematic review and meta-analysis of those RCTs to provide an overall summation of evidence that can potentially be considered for further regulatory decisions, including reimbursement policies. We searched for RCTs in MEDLINE, Embase, and the Cochrane Central Register of Controlled Trials from their inception to January 31, 2018. Our meta-analysis of 30 RCTs confirmed that propofol sedation had advantages in recovery time when compared with other drugs, without excessive concerns for cardiovascular or respiratory adverse events. Its safety profile regarding coughing, nausea or vomiting, and emergence delirium was also similar to that of other drugs. The overall evidence suggests that propofol sedation for paediatric procedures should be considered more positively in the context of regulatory decisions.

1 January 2019 in Journal of Korean Medical Science
Verified
Journal Article
Open access
HHHyunsook Hong
Hyunsook Hong
SHSeokyung Hahn
Seokyung Hahn
YCYunhee Choi
Yunhee Choi
MJMyoung-Jin Jang
Myoung-Jin Jang
SKSunhee Kim
Sunhee Kim
HKHee-Soo KIM
Hee-Soo KIM
Hong H, et al. J Korean Med Sci. 2019 Apr;34(15):e124. https://doi.org/10.3346/jkms.2019.34.e124